Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ) shares traded up 3.4% during mid-day trading on Thursday . The company traded as high as $28.67 and last traded at $28.58, with a volume of 250,188 shares changing hands. The stock had previously closed at $27.65.

A number of research analysts recently issued reports on the company. Brean Capital restated a “buy” rating on shares of Zeltiq Aesthetics in a research report on Thursday, April 28th. TheStreet lowered Zeltiq Aesthetics from a “buy” rating to a “hold” rating in a research report on Friday, June 10th. Stifel Nicolaus restated a “buy” rating and set a $38.00 price objective on shares of Zeltiq Aesthetics in a research report on Friday, May 13th. Piper Jaffray Cos. restated an “overweight” rating and set a $40.00 price objective on shares of Zeltiq Aesthetics in a research report on Monday, May 2nd. Finally, Goldman Sachs Group Inc. boosted their price objective on Zeltiq Aesthetics from $35.00 to $37.00 in a research report on Friday, April 8th. Two research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $36.25.

The company has a 50 day moving average price of $27.55 and a 200-day moving average price of $26.14. The stock has a market cap of $1.14 billion and a P/E ratio of 34.79.

Zeltiq Aesthetics (NASDAQ:ZLTQ) last posted its quarterly earnings results on Tuesday, May 10th. The company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25). The firm earned $64.50 million during the quarter, compared to analyst estimates of $61.80 million. The company’s revenue was up 25.0% on a year-over-year basis. During the same period last year, the company earned ($0.06) EPS. On average, analysts forecast that Zeltiq Aesthetics Inc. will post $0.01 earnings per share for the current fiscal year.

In other news, Director Mary Fisher sold 1,863 shares of the stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $30.00, for a total value of $55,890.00. Following the completion of the transaction, the director now directly owns 3,923 shares of the company’s stock, valued at approximately $117,690. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Mark J. Foley sold 13,640 shares of the stock in a transaction that occurred on Wednesday, April 13th. The stock was sold at an average price of $29.39, for a total value of $400,879.60. Following the completion of the transaction, the chief executive officer now directly owns 353,063 shares of the company’s stock, valued at $10,376,521.57. The disclosure for this sale can be found here.

Several institutional investors recently modified their holdings of the company. Trexquant Investment LP bought a new position in shares of Zeltiq Aesthetics during the fourth quarter worth about $1,640,000. Wells Fargo & Company MN boosted its position in shares of Zeltiq Aesthetics by 765.2% in the fourth quarter. Wells Fargo & Company MN now owns 404,376 shares of the company’s stock worth $11,537,000 after buying an additional 357,636 shares during the last quarter. CAM Group Holding A S boosted its position in shares of Zeltiq Aesthetics by 100.0% in the fourth quarter. CAM Group Holding A S now owns 150,000 shares of the company’s stock worth $4,280,000 after buying an additional 75,000 shares during the last quarter. EAM Investors LLC boosted its position in shares of Zeltiq Aesthetics by 3.5% in the fourth quarter. EAM Investors LLC now owns 78,374 shares of the company’s stock worth $2,236,000 after buying an additional 2,670 shares during the last quarter. Finally, New York State Common Retirement Fund boosted its position in shares of Zeltiq Aesthetics by 4.3% in the fourth quarter. New York State Common Retirement Fund now owns 41,532 shares of the company’s stock worth $1,185,000 after buying an additional 1,700 shares during the last quarter.

ZELTIQ Aesthetics, Inc is a medical technology company. The Company is focused on developing and commercializing products utilizing its controlled-cooling technology platform. Its commercial product, the CoolSculpting System, is designed to reduce stubborn fat bulges. The Company sells its CoolSculpting system to dermatologists, plastic surgeons and aesthetic specialists and generates revenue from sales of its CoolSculpting system and from sales of consumables to its customers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.